The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000613303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
16/11/2025
Date registered
Help: Date registered
18/05/2026
Date last updated
Help: Date last updated
18/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
18/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Investigating the clinical utility of new probiotic strains in a health adult population - Stage 1
Scientific title
Investigating the clinical utility of new probiotic strains in a health adult population - Stage 1
Additional trial identifiers [1] 315791 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Gastrointestinal flora 339547 0
Condition category
Condition code
Oral and Gastrointestinal 335793 335793 0 0
Normal oral and gastrointestinal development and function

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The probiotic will be a combination of novel strains collectively referred to MTC01. There are 3 planned phases where an individual participant will receive only one group of strains with the composition to be determined based on the microbial analyses in the preceding phase. Only the first phase has been defined at this point in time.

The first phases will have intermittent dosing face to face with the study coordinators at Day 0, 3 and 7 where capsules will be administered to achieve a dose of 5-6x109 in 15 or fewer capsules.

In each phase there will be 2 groups, 1 receiving high and low dose therapy. Low dose subjects will receive capsules formulated to achieve a dose of 5x109 (2x108 – 5x109) in 15 or fewer capsules, while high dose subjects will receive a dose of 2.6x1011 (1x1010 – 5x1011) in 15 or fewer capsules
Intervention code [1] 332419 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 343327 0
Engraftment of individual probiotic strains in the recipient
Timepoint [1] 343327 0
28 days post first probiotic dose.
Secondary outcome [1] 454059 0
Change in metabolic function
Timepoint [1] 454059 0
28 days post first probiotic dose
Secondary outcome [2] 454060 0
Safety of administration
Timepoint [2] 454060 0
28 days post first dose.

Eligibility
Key inclusion criteria
• Aged >18
• Healthy participants
• Able to provide informed consent + willing to collect required samples during the study period.
• Ability to attend in-person visits during the trial period
• Ability to appropriately store investigative product in a freezer
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Any concurrent medical conditions, including but not limited to
o IBD/IBS, Cancer, Metabolic syndrome,
• Antibiotics or probiotics within 4 weeks of enrolment
• Patients unable to give informed consent
• Currently pregnant or planning for pregnancy within the next 6 months.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 320399 0
Hospital
Name [1] 320399 0
St Vincent's Hospital Sydney
Country [1] 320399 0
Australia
Primary sponsor type
University
Name
University of New South Wales
Address
Country
Australia
Secondary sponsor category [1] 323100 0
None
Name [1] 323100 0
Address [1] 323100 0
Country [1] 323100 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318946 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 318946 0
Ethics committee country [1] 318946 0
Australia
Date submitted for ethics approval [1] 318946 0
07/04/2025
Approval date [1] 318946 0
21/05/2025
Ethics approval number [1] 318946 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 145758 0
A/Prof Craig Haifer
Address 145758 0
St Vincent's Hospital Sydney, 390 Victoria St, Darlinghurst, 2010, NSW
Country 145758 0
Australia
Phone 145758 0
+61 02 8382 2388
Fax 145758 0
Email 145758 0
Contact person for public queries
Name 145759 0
Craig Haifer
Address 145759 0
St Vincent's Hospital Sydney 390 Victoria St, Darlinghurst, 2010, NSW
Country 145759 0
Australia
Phone 145759 0
+61 02 8382 2388
Fax 145759 0
Email 145759 0
Contact person for scientific queries
Name 145760 0
Craig Haifer
Address 145760 0
St Vincent's Hospital Sydney 390 Victoria St, Darlinghurst, 2010, NSW
Country 145760 0
Australia
Phone 145760 0
+61 02 8382 2388
Fax 145760 0
Email 145760 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.